Cargando…
Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and its subvariants (BA.2, BA.4, BA.5) represented the most commonly circulating variants of concern (VOC) in the coronavirus disease 2019 (COVID-19) pandemic in 2022. Despite high vaccination rates with approved SARS-CoV-2 vaccine...
Autores principales: | Roth, Nicole, Gergen, Janina, Kovacikova, Kristina, Mueller, Stefan O., Ulrich, Lorenz, Schön, Jacob, Halwe, Nico Joel, Fricke, Charlie, Corleis, Björn, Dorhoi, Anca, Hoffmann, Donata, Beer, Martin, Maione, Domenico, Petsch, Benjamin, Rauch, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965737/ https://www.ncbi.nlm.nih.gov/pubmed/36851196 http://dx.doi.org/10.3390/vaccines11020318 |
Ejemplares similares
-
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
por: Corleis, Björn, et al.
Publicado: (2023) -
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Hoffmann, Donata, et al.
Publicado: (2021) -
Animal models for COVID-19 and tuberculosis
por: Corleis, Björn, et al.
Publicado: (2023) -
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses
por: Roth, Nicole, et al.
Publicado: (2022) -
Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)